AlzeCure Pharma: Rights issue oversubscribed - Redeye

Redeye comments on the outcome of AlzeCure’s rights issue, which was significantly oversubscribed at 212%, raising net SEK55.5m. The strong investor interest, combined with the exercise of the overallotment option, reflects growing market confidence in the company’s pipeline and strategic direction.

Länk till analysen i sin helhet: https://www.redeye.se/research/1120785/alzecure-pharma-rights-issue-oversubscribed?utm_source=finwire&utm_medium=RSS